|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
gptkb:COVAX
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:booster_recommendation
|
not initially required
|
|
gptkbp:clinical_trial
|
over 40,000
multiple countries
Phase 3
|
|
gptkbp:clinical_trial_results_published_in
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:developed_by
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:distribution
|
global
|
|
gptkbp:dosage_form
|
1 dose
|
|
gptkbp:efficacy_against_severe_disease
|
85% effective
|
|
gptkbp:emergency_services
|
for high-risk populations
|
|
gptkbp:first_emergency_use_authorization
|
February 27, 2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen's COVID-19 vaccine
|
|
gptkbp:informed_consent_required
|
gptkb:true
|
|
gptkbp:is_effective_against
|
approximately 66% effective
|
|
gptkbp:is_vulnerable_to
|
gptkb:significant
gptkb:complex
gptkb:WHO
international organizations
mixed
various governments
refrigerated
government and private sources
logistical issues
less than a year
reduced hospitalization rates
viral vector platform
February 27, 2021
important for uptake
monovalent
|
|
gptkbp:manufacturer
|
gptkb:United_States
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:mechanism_of_action
|
uses a modified adenovirus
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:safety_measures
|
VAERS
|
|
gptkbp:shelf_life
|
up to 3 months
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
nausea
fever
mandatory
|
|
gptkbp:target_audience
|
adults 18 years and older
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vaccine_administration_route
|
intramuscular
|
|
gptkbp:vaccine_clinical_trial_locations
|
gptkb:Africa
gptkb:Europe
gptkb:Asia
gptkb:North_America
gptkb:South_America
|
|
gptkbp:vaccine_communication_strategy
|
public health campaigns
|
|
gptkbp:vaccine_crisis_management
|
part of pandemic response
|
|
gptkbp:vaccine_distribution_partnerships
|
various NGOs
|
|
gptkbp:vaccine_effectiveness_against_variants
|
variable
|
|
gptkbp:vaccine_efficacy_duration
|
at least 8 months
|
|
gptkbp:vaccine_future_research
|
ongoing studies.
|
|
gptkbp:vaccine_global_access
|
aimed for equitable access
|
|
gptkbp:vaccine_impact_on_transmission
|
reduced transmission rates
|
|
gptkbp:vaccine_long_term_effects
|
under investigation
|
|
gptkbp:vaccine_monitoring_system
|
active surveillance
|
|
gptkbp:vaccine_public_health_guidelines
|
followed by health authorities
|
|
gptkbp:vaccine_research_ethics
|
adhered to guidelines
|
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
|
|
gptkbp:bfsLayer
|
6
|